Watch Desk posted an update
In early drug discovery, adding more tools does not guarantee better decisions. Dr Harsh Shah’s practical advice is to start with a specific scientific question and make it possible to trace a decision back through its evidence, methods and limitations.
Why it mattersFor AI, that means recording the model version and input data alongside its recommendation, then checking it against new experiments. Shah also suggests measuring whether a workflow improves decisions, rather than counting connected systems or records moved. A dashboard full of data is not, by itself, a scientific breakthrough. His article in Drug Target Review sets out a useful test for teams adopting AI: can they explain what evidence supported a decision, who reviewed it and what happened next?
Discuss: Should drug-discovery teams require prospective experimental testing before acting on an AI recommendation, or can a traceable record and expert review be enough?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.